Document Detail


Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.
MedLine Citation:
PMID:  23332364     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In 2010, we put forward a hypothetical model of the major biomarkers of Alzheimer's disease (AD). The model was received with interest because we described the temporal evolution of AD biomarkers in relation to each other and to the onset and progression of clinical symptoms. Since then, evidence has accumulated that supports the major assumptions of this model. Evidence has also appeared that challenges some of our assumptions, which has allowed us to modify our original model. Refinements to our model include indexing of individuals by time rather than clinical symptom severity; incorporation of interindividual variability in cognitive impairment associated with progression of AD pathophysiology; modifications of the specific temporal ordering of some biomarkers; and recognition that the two major proteinopathies underlying AD biomarker changes, amyloid β (Aβ) and tau, might be initiated independently in sporadic AD, in which we hypothesise that an incident Aβ pathophysiology can accelerate antecedent limbic and brainstem tauopathy.
Authors:
Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Related Documents :
24494614 - Statistical thermodynamics concepts and mathematical tools for a multi-agent ecosystem.
12429564 - Unravelling mechanisms underlying ischaemic arrhythmias - the importance of models.
22970794 - Simulation evaluation of statistical properties of methods for indirect and mixed treat...
23539504 - Bayesian thurstonian models for ranking data using jags.
24197224 - Selecting the size of a diallel cross experiment.
2319094 - The effect of size on paired 'c/d' estimations.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  The Lancet. Neurology     Volume:  12     ISSN:  1474-4465     ISO Abbreviation:  Lancet Neurol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-21     Completed Date:  2013-03-17     Revised Date:  2014-08-15    
Medline Journal Info:
Nlm Unique ID:  101139309     Medline TA:  Lancet Neurol     Country:  England    
Other Details:
Languages:  eng     Pagination:  207-16     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alzheimer Disease / cerebrospinal fluid,  pathology,  physiopathology*
Amyloid beta-Peptides / cerebrospinal fluid
Biological Markers / cerebrospinal fluid*
Cognition Disorders / etiology
Humans
Models, Biological*
Nonlinear Dynamics*
tau Proteins / cerebrospinal fluid
Grant Support
ID/Acronym/Agency:
AG11378/AG/NIA NIH HHS; R01 AG011378/AG/NIA NIH HHS
Chemical
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Biological Markers; 0/tau Proteins
Comments/Corrections
Comment In:
Lancet Neurol. 2013 Feb;12(2):126-8   [PMID:  23332358 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment.
Next Document:  Development of the Davos Assessment of Cognitive Biases Scale (DACOBS).